Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

MTLS vs VIVS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MTLS Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–0 Matrix Metrics)

MTLS Overall Winner 6-Pillar Tally: MTLS 6 – 0 VIVS Matrix Metrics: MTLS 9 – 0 VIVS

As of Nov 19, 2026, Materialise NV (MTLS) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MTLS carries a Unified Composite Score of 64.7/100 (BUY) at $6.31 (N/M Forward P/E, 3.4% operating margin), whereas VIVS carries 36.8/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin).

  • Technical & Structure Timing Caution: MTLS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 32.7); meanwhile VIVS is in a Breakdown options structure phase (RSI 75.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MTLS vs VIVS
MTLS NASDAQ Head-to-Head Winner
Materialise NV
Services-Prepackaged Software
$6.31
-0.79% 1D
Market Cap $371.1M
TTM Revenue $605M
Forward P/E N/M
Beta / 30D Vol 1.12β · 87% Vol
Unified Composite Score
64.7 / 100 BUY
Tech 68.0 Fund 66.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 33
RSI-14: 32.7 · SMA20: $7.06 · SMA50: $7.73
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
TTM Revenue $112,000
Forward P/E N/M
Beta / 30D Vol 0.83β · 480% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 5.0 Fund 38.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 75
RSI-14: 75.1 · SMA20: $0.15 · SMA50: $0.18

6-Pillar Scorecard Institutional Category Breakdown (MTLS 6 – 0 VIVS)

Columns: Metric · MTLS · VIVS
1. Valuation Multiples MTLS
Forward P/E N/M N/M
Trailing P/E 25.0x N/M
PEG Ratio 1.26x N/M
EV / Revenue 0.6x 9.6x
2. Growth & Scale MTLS
Revenue Growth (YoY) +2.1% -51.4%
Earnings Growth (YoY) -33.3% +0.0%
TTM Revenue (USD) $605M $112,000
Market Cap $371.1M $2.4M
3. Profitability & Quality MTLS
Gross Margin 57.4% N/A
Operating Margin 3.4% -10117.0%
Net Profit Margin 4.6% 0.0%
Return on Equity (ROE) 5.0% -343.1%
4. Balance Sheet & Cash Flow MTLS
Cash Generation (TTM) $55M EBITDA -$11M EBITDA
Cash Flow Margin 9.1% EBITDA Mgn N/A
Net Cash / Leverage $4.97 Book/Sh · 5.0% ROE $1.4M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MTLS
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat MTLS
OpEx & R&D Intensity 54.0% of Rev ($327M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Software - Application Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MTLS (9) vs VIVS (0)
Institutional Metric MTLS VIVS Criterion Row Edge
Market Capitalization
Scale
$371.1M $2.4M Larger Scale MTLS
Trailing P/E Ratio
Valuation
25.0x N/M Lower Multiple MTLS
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+2.1% -51.4% Higher Growth MTLS
Operating Margin (TTM)
Profitability
3.4% -10117.0% Higher Margin MTLS
Net Profit Margin
Profitability
4.6% 0.0% Higher Margin MTLS
Return on Equity (ROE)
Capital Efficiency
5.0% -343.1% Higher ROE MTLS
52-Week Range Position
Momentum
38% ($5–$9) 5% ($0–$3) Stronger Trend MTLS
Beta / 30D Volatility
Risk Regime
1.12β · 87% Vol 0.83β · 480% Vol Lower Realized Risk MTLS
Unified Institutional Score
Composite Signal
64.7 / 100 (BUY) 36.8 / 100 (SELL) Higher Composite MTLS
Trailing 12M Revenue (USD)
Operating Scale
$605M $112,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
57.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.26x PEG · 0.6x EV/Rev N/M PEG · 9.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$55M EBITDA ($4.97 Book/Sh · 5.0% ROE) -$11M EBITDA ($1.4M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VIVS +90.19 pp
MTLS: -25.5% · VIVS: +64.69%
3M Horizon VIVS +6.46 pp
MTLS: -4.54% · VIVS: +1.92%
6M Horizon MTLS +86.67 pp
MTLS: +8.42% · VIVS: -78.25%
1Y Horizon MTLS +88.44 pp
MTLS: +1.45% · VIVS: -86.99%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MTLS vs VIVS. Trailing 12-month operating profitability (MTLS 3.4% vs VIVS -10117.0%) and valuation multiples (MTLS N/M vs VIVS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MTLS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$605M
Gross Margin57.4%
Op. Margin3.4%
ROE / Fwd P/E5.0% · N/M
VIVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$112,000
Gross MarginN/A
Op. Margin-10117.0%
ROE / Fwd P/E-343.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MTLS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MTLS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VIVS BREAKDOWN
73d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact VIVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MTLS Moat Profile Cyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $371.1M market capitalization and 3.4% operating margin.
OpEx & R&D Reinvestment 54.0% of Rev ($327M)
90D Engineering Disclosures 0 Published
VIVS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4M market capitalization and -10117.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MTLS vs VIVS Key Questions & Quantitative Answers

As of Nov 19, 2026, Materialise NV (MTLS) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MTLS carries a Unified Composite Score of 64.7/100 (BUY) at $6.31 (N/M Forward P/E, 3.4% operating margin), whereas VIVS carries 36.8/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin). Technical & Structure Timing Caution: MTLS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 32.7); meanwhile VIVS is in a Breakdown options structure phase (RSI 75.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MTLS leads the Growth & Scale pillar: MTLS posts +2.1% YoY revenue growth and -33.3% YoY earnings growth on $605M TTM revenue (57.4% gross margin, 3.4% operating margin), compared with VIVS at -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin). On trailing 12-month operating scale, MTLS generates $605M in USD-normalized revenue versus $112,000 for VIVS. In operating R&D and SG&A reinvestment, MTLS deploys 54.0% of Rev ($327M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VIVS.

MTLS screens cheaper on headline valuation multiples. MTLS trades at N/M Forward P/E, 25.0x Trailing P/E, 1.26x PEG, and 0.6x EV/Revenue (9.1% EBITDA margin), whereas VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MTLS (5.0% ROE) versus VIVS (-343.1% ROE) capital efficiency.

In options market volatility and institutional positioning, MTLS carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.12β · 87% Vol realized risk). By comparison, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.